Skip to content

HEmiplegia Arrhythmia Retrospective Trial

Role of Alternating Hemiplegia of Childhood Genotype in Cardiac Repolarization. HEART: HEmiplegia Arrhythmia Retrospective Trial

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04944927
Acronym
HEART
Enrollment
20
Registered
2021-06-30
Start date
2021-04-29
Completion date
2022-06-29
Last updated
2023-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alternating Hemiplegia of Childhood

Keywords

QTc, Cardiac repolarization and arrhythmia, ECG, Alternating Hemiplegia

Brief summary

Alternating Hemiplegia of Childhood (AHC) is a rare and severe disease that is in need of effective, and hopefully even curative, therapies. Afflicted patients suffer from severe paralyzing crises, often excruciatingly painful muscle spasms, severe often life threatening epileptic seizures, frequently severe developmental and psychiatric/psychological disabilities and other comorbidities, such as cardiac disturbances. Recent data indicate that AHC genotype is in relation to cardiac repolarization troubles and to cardiac arrhythmias. The primary hypothesis to explore is that there is an association between genotype and cardiac phenotype in AHC.

Interventions

OTHERRecording of clinical parameters and electrocardiogram parameters

Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Months to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients that meet the clinical diagnostic criteria (Aicardi et al, 1995) for typical alternating hemiplegia with or without identified mutations in ATP1A3. * At least one ECG study is required. * Patients ages yearand more

Exclusion criteria

* Informed consent or assent not obtainable * ATP1A3 testing not performed * No ECG studies are available

Design outcomes

Primary

MeasureTime frameDescription
Measurement of QTc interval and all relevant cardiac repolarization measurementsDay 1Outcome measure: QTc interval and cardiac repolarization measurement in milliseconds.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026